Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
EFFECTS OF LORAZEPAM ADMINISTRATION ON STRIATAL DOPAMINE D-2 RECEPTOR-BINDING CHARACTERISTICS IN MAN - A POSITRON EMISSION TOMOGRAPHY STUDY
Autore:
HIETALA J; KUOPPAMAKI M; NAGREN K; LEHIKOINEN P; SYVALAHTI E;
Indirizzi:
UNIV TURKU,CENT HOSP,DEPT PSYCHIAT 721 FIN-20520 TURKU FINLAND UNIV TURKU,DEPT PHARMACOL & CLIN PHARMACOL FIN-20520 TURKU FINLAND UNIV TURKU,CENT HOSP,PET CTR,TURKU MED CYCLOTRON FIN-20520 TURKU FINLAND
Titolo Testata:
Psychopharmacology
fascicolo: 4, volume: 132, anno: 1997,
pagine: 361 - 365
Fonte:
ISI
Lingua:
ENG
Soggetto:
NAIVE SCHIZOPHRENIC-PATIENTS; SEROTONERGIC MODULATION; GABAERGIC NEURONS; CINGULATE CORTEX; C-11 RACLOPRIDE; IN-VIVO; BENZODIAZEPINES; BRAIN; LOCALIZATION; METABOLISM;
Keywords:
BENZODIAZEPINE; LORAZEPAM; DOPAMINE; POSITRON EMISSION TOMOGRAPHY; RACLOPRIDE PSYCHOSIS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
31
Recensione:
Indirizzi per estratti:
Citazione:
J. Hietala et al., "EFFECTS OF LORAZEPAM ADMINISTRATION ON STRIATAL DOPAMINE D-2 RECEPTOR-BINDING CHARACTERISTICS IN MAN - A POSITRON EMISSION TOMOGRAPHY STUDY", Psychopharmacology, 132(4), 1997, pp. 361-365

Abstract

Lorazepam is a widely used benzodiazepine class anxiolytic drug. It is known to enhance GABAergic neurotransmission in the brain, but the actions of benzodiazepines on other neurotransmitter systems are largely unknown. We studied the effects of 1 week's administration with lorazepam (2 mg daily, PO) or placebo on striatal D-2 dopamine receptors in four healthy male volunteers using a double-blind randomized cross-over design. D-2 receptor density and affinity as well as binding potential (B-max/K-d) were measured with [C-11]-raclopride and positron emission tomography. Although the individual responses varied, lorazepam did not significantly affect D-2 receptor binding characteristics, nordid the average effect sizes exceed test-retest variability of the method. In conclusion, the results suggest that striatal D-2 dopamine receptor characteristics are not affected by the clinically relevant lorazepam treatment regimen used.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/01/20 alle ore 14:00:32